EP Patent

EP2190837A1 — 4-pyrimidinesulfamide derivative

Assigned to Actelion Pharmaceuticals Ltd · Expires 2010-06-02 · 16y expired

What this patent protects

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.

USPTO Abstract

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.

Drugs covered by this patent

Patent Metadata

Patent number
EP2190837A1
Jurisdiction
EP
Classification
—
Expires
2010-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.